Agilent Technologies’ New Pharmaceutical Facility, Frederick, Colorado, United States of America

Agilent Technologies

Agilent Technologies initiated the construction of a new multi-structure pharmaceutical manufacturing plant at Frederick in Weld County, Colorado, US, in October 2016. Construction of the new facility is aimed at doubling Agilent's production capacity of nucleic acid active pharmaceutical ingredients (APIs).

Agilent is investing $120m into the new facility, which is expected to be operational by the end of 2017.

The facility will create more than 200 high-paid jobs for skilled workers, attract new investment, and improve the local economy in northern Colorado.

Locations details of Agilent's API facility

Agilent's new facility is being built on a 20-acre site acquired in Eagle Business Park in Frederick. The site is situated north-west of the intersection of Tipple Parkway and Silver Birch Boulevard, which is close to the junction of Interstate 25 and Colorado Highway 52.

"The facility will create more than 200 high-paid jobs for skilled workers, attract new investment, and improve the local economy in northern Colorado."

Agilent initially considered Austin and Texas for the construction of the facility, but finally preferred Frederick due to its proximity to Boulder.

Land for the construction was purchased from USE Real Estate Holdings for $1.83m.

Agilent's new pharmaceutical facility details

The new API facility will include 130,000ft² of new structures such as a production building, a bulk tank farm and a lab/office building. It will be equipped with a single production train, along with sufficient space and utilities to add a second train in the future.

Space for future expansion phases will also be available.

Production at the new facility

Agilent's nucleic acid APIs business is an integral part of the diagnostics and genomics division.

In order to cater the increased demand for nucleic acid solutions, the new facility will enable Agilent to produce oligonucleotides, which are the short DNA and RNA molecules.

Agilent supplies oligonucleotides to a range of customers, including AstraZeneca, Biomarin and others. Oligonucleotides are used to develop a range of treatments for indications such as cancer, diabetes, muscular dystrophy and other disorders.

Contractors involved

CRB was contracted to provide design and engineering services for the new pharmaceutical facility, while GE Johnson Construction Company was contracted to offer construction management and serve as general contractor for the project.

Marketing commentary on Agilent Technologies

Headquartered in Santa Clara, California, Agilent Technologies specialises in providing solutions for life sciences, diagnostics and applied chemical markets. The company also offers instruments, software, services, consumables, applications and expertise for laboratories globally.

Agilent also provides services ranging from disease research and drug discovery to drug development, manufacturing, stability studies, regulatory support and quality control to the pharmaceutical industry. The company serves customers located in more than 100 countries and has over 12,000 employees.

The company commenced operations in Colorado with the acquisition of the Boulder manufacturing facility from SynPro Corporation in 2006. The plant was expanded in 2008 after purchasing the nucleic acid business from Downpharma.

A second expansion took place in 2010 to make it capable of producing several hundred kilograms of commercial therapeutic oligonucleotides a year.